Finch Therapeutics Group (FNCH) Stock Forecast, Price Target & Predictions
FNCH Stock Forecast
Finch Therapeutics Group stock forecast is as follows: an average price target of $15.30K (represents a 127400.00% upside from FNCH’s last price of $12.00) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
FNCH Price Target
The average price target for Finch Therapeutics Group (FNCH) is $15.30K based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $15.30K to $15.30K. This represents a potential 127400.00% upside from FNCH's last price of $12.00.
FNCH Analyst Ratings
According to 1 Wall Street analysts, Finch Therapeutics Group's rating consensus is 'Buy'. The analyst rating breakdown for FNCH stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Finch Therapeutics Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 05, 2022 | Roger Song | Jefferies | $15.30K | $4.43K | 245.53% | 127400.00% |
The latest Finch Therapeutics Group stock forecast, released on Apr 05, 2022 by Roger Song from Jefferies, set a price target of $15.30K, which represents a 245.53% increase from the stock price at the time of the forecast ($4.43K), and a 127400.00% increase from FNCH last price ($12.00).
Finch Therapeutics Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $12.00 | $12.00 | $12.00 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Finch Therapeutics Group stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Finch Therapeutics Group's last price of $12.00. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 05, 2022 | Jefferies | Buy | Buy | Hold |
Finch Therapeutics Group's last stock rating was published by Jefferies on Apr 05, 2022. The company gave FNCH a "Buy" rating, the same as its previous rate.
Finch Therapeutics Group Financial Forecast
Finch Therapeutics Group Revenue Forecast
| Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | $8.00K | $138.00K | $361.00K | $806.00K | $3.55M |
| Avg Forecast | - | - | $400.00K | $750.00K | $650.00K | $5.00M | $3.60M |
| High Forecast | - | - | $400.00K | $750.00K | $650.00K | $5.00M | $3.60M |
| Low Forecast | - | - | $400.00K | $750.00K | $650.00K | $5.00M | $3.60M |
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | 0.02% | 0.18% | 0.56% | 0.16% | 0.99% |
Finch Therapeutics Group's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. FNCH's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $8.00K (Dec 22).
Finch Therapeutics Group EBITDA Forecast
| Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | $-27.27M | $-573.00K | $-19.45M | $-18.38M | $-13.61M |
| Avg Forecast | - | - | $-400.00K | $-750.00K | $-650.00K | $-5.00M | $-26.55M |
| High Forecast | - | - | $-400.00K | $-750.00K | $-650.00K | $-5.00M | $-21.24M |
| Low Forecast | - | - | $-400.00K | $-750.00K | $-650.00K | $-5.00M | $-31.85M |
| Surprise % | - | - | 68.17% | 0.76% | 29.93% | 3.68% | 0.51% |
undefined analysts predict FNCH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Finch Therapeutics Group's previous annual EBITDA (undefined) of $NaN.
Finch Therapeutics Group Net Income Forecast
| Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | $-26.32M | $-40.11M | $-22.77M | $-19.05M | $-13.98M |
| Avg Forecast | $2.48M | $2.16M | $-15.90M | $-20.23M | $-20.71M | $-15.42M | $-27.26M |
| High Forecast | $2.48M | $2.16M | $-15.90M | $-20.23M | $-20.71M | $-15.42M | $-21.81M |
| Low Forecast | $2.48M | $2.16M | $-15.90M | $-20.23M | $-20.71M | $-15.42M | $-32.72M |
| Surprise % | - | - | 1.66% | 1.98% | 1.10% | 1.24% | 0.51% |
Finch Therapeutics Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FNCH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Finch Therapeutics Group SG&A Forecast
| Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | $10.94M | $9.58M | $8.16M | $5.07M | $4.55M |
| Avg Forecast | - | - | $23.95M | $44.91M | $38.93M | $299.43M | $215.59M |
| High Forecast | - | - | $23.95M | $44.91M | $38.93M | $299.43M | $215.59M |
| Low Forecast | - | - | $23.95M | $44.91M | $38.93M | $299.43M | $215.59M |
| Surprise % | - | - | 0.46% | 0.21% | 0.21% | 0.02% | 0.02% |
Finch Therapeutics Group's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to FNCH last annual SG&A of $10.94M (Dec 22).
Finch Therapeutics Group EPS Forecast
| Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | $-0.55 | $-0.84 | $-0.48 | $-0.40 | $-1.00 |
| Avg Forecast | $1.54 | $1.34 | $-9.90 | $-12.60 | $-12.90 | $-9.60 | $-30.00 |
| High Forecast | $1.54 | $1.34 | $-9.90 | $-12.60 | $-12.90 | $-9.60 | $-30.00 |
| Low Forecast | $1.54 | $1.34 | $-9.90 | $-12.60 | $-12.90 | $-9.60 | $-30.00 |
| Surprise % | - | - | 0.06% | 0.07% | 0.04% | 0.04% | 0.03% |
According to undefined Wall Street analysts, Finch Therapeutics Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FNCH previous annual EPS of $NaN (undefined).
Finch Therapeutics Group Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FNCH | Finch Therapeutics Group | $12.00 | $15.30K | 127400.00% | Buy |
| KPRX | Kiora Pharmaceuticals | $3.52 | $120.00 | 3309.09% | Buy |
| BWV | Onconetix | $0.18 | $4.00 | 2122.22% | Buy |
| XLO | Xilio Therapeutics | $1.29 | $7.00 | 442.64% | Buy |
| HOWL | Werewolf Therapeutics | $2.44 | $12.00 | 391.80% | Buy |
| LGVN | Longeveron | $2.15 | $10.00 | 365.12% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| STOK | Stoke Therapeutics | $13.25 | $30.60 | 130.94% | Buy |
| CCCC | C4 Therapeutics | $5.97 | $13.50 | 126.13% | Buy |
| CELC | Celcuity | $16.25 | $31.50 | 93.85% | Buy |
| DSGN | Design Therapeutics | $5.94 | $9.67 | 62.79% | Buy |
| EWTX | Edgewise Therapeutics | $36.62 | $45.00 | 22.88% | Buy |
| IKNA | Ikena Oncology | $1.72 | $1.33 | -22.67% | Buy |
FNCH Forecast FAQ
Is Finch Therapeutics Group a good buy?
Yes, according to 1 Wall Street analysts, Finch Therapeutics Group (FNCH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of FNCH's total ratings.
What is FNCH's price target?
Finch Therapeutics Group (FNCH) average price target is $15.3K with a range of $15.3K to $15.3K, implying a 127400.00% from its last price of $12. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Finch Therapeutics Group stock go up soon?
According to Wall Street analysts' prediction for FNCH stock, the company can go up by 127400.00% (from the last price of $12 to the average price target of $15.3K), up by 127400.00% based on the highest stock price target, and up by 127400.00% based on the lowest stock price target.
Can Finch Therapeutics Group stock reach $20?
FNCH's average twelve months analyst stock price target of $15.3K supports the claim that Finch Therapeutics Group can reach $20 in the near future.
Did the FNCH's actual financial results beat the analysts' financial forecasts?
Based on Finch Therapeutics Group's last annual report (Dec 2022), the company's revenue was $861K, which missed the average analysts forecast of $1.8M by -52.17%. Apple's EBITDA was $-74.647M, beating the average prediction of $-1.8M by 4047.06%. The company's net income was $-114M, beating the average estimation of $-56.844M by 100.02%. Apple's SG&A was $38.09M, missing the average forecast of $107.79M by -64.67%. Lastly, the company's EPS was $-2.38, missing the average prediction of $-35.4 by -93.28%. In terms of the last quarterly report (Dec 2022), Finch Therapeutics Group's revenue was $8K, missing the average analysts' forecast of $400K by -98.00%. The company's EBITDA was $-27.266M, beating the average prediction of $-400K by 6716.50%. Finch Therapeutics Group's net income was $-26.322M, beating the average estimation of $-15.897M by 65.58%. The company's SG&A was $10.94M, missing the average forecast of $23.95M by -54.35%. Lastly, the company's EPS was $-0.55, missing the average prediction of $-9.9 by -94.44%